NCT05775341

Brief Summary

The goal of this observational study is to contribute to a better understanding of the perioperative kinetics of intestinal microbial composition and association with surgical site infections. The main question this study aims to determine if:

  • Patients undergoing surgery develop transient intestinal dysbiosis
  • Such transient dysbiosis is associated with translocation to the systemic circulation and surgical site infection Patients undergoing elective abdominal surgery will be included prospectively. Informed consent will be obtained. From patients the following information and samples will be collected:
  • Perioperative: Baseline health data, nutrition data, measurement body composition, glucose monitoring
  • Intraoperatively:
  • Mucosal swabs
  • Blood from central venous catheter and portal vein
  • Mesenteric lymph node
  • Intestinal specimen
  • Bile
  • Subcutaneous biopsy
  • Postoperatively:
  • If a surgical site infection occurs samples from infected site

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Feb 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Feb 2023Dec 2026

Study Start

First participant enrolled

February 27, 2023

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

March 7, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 20, 2023

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

3.8 years

First QC Date

March 7, 2023

Last Update Submit

April 28, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes of the intestinal microbiome between start and end of surgery

    Score between PCA (principal components analysis) in the intestine between start (T1) and end (T2) of surgery. * Sampling: An intestinal specimen is dissected at start and end of elective pancreatic resections. * Processing: Samples are immediately processed for storage at -80° in glycerol. * Analysis: Quantification of total Biomass, DNA extraction, preparation of Bacterial DNA libraries, sequencing with Illumina system, downstream analysis, statistical analysis, principal components analysis (PCA) with all the samples is performed and the score is defined based on the distance between the two centers in PC1 and PC2 of T1 versus T2.

    Day 0 (Day of Surgery)

Secondary Outcomes (4)

  • Bacterial taxonomy in the intestine

    Day 0 (Day of Surgery)

  • Bacterial taxonomy MLN

    Day 0 (Day of Surgery)

  • Bacterial taxonomy mucosal swabs

    Day 0 (Day of Surgery)

  • Bacterial taxonomy in the blood

    Day 0 (Day of Surgery)

Interventions

This is purely an observational study.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients undergoing elective abdominal surgery

You may qualify if:

  • Patients undergoing laparoscopic colorectal resection with anastomosis or patients undergoing duodeno-pancreatectomy.
  • Elective surgery
  • Informed consent
  • Age \> 18 years

You may not qualify if:

  • Emergency surgery
  • Other surgery 30 days prior to surgery
  • BMI \<18 or \>50kg/m2
  • Planed simultaneous second procedure with involvement of the intestinal tract
  • Cholestasis with cholangitis, hepatic disease (defined as cirrhosis Child B or C) or renal disease (acute or chronic renal failure defined as eGFR≤ 30ml/min)
  • Severe active enteritis or colitis, malabsorption, enteric infections
  • Pancreatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beldi Guido

Bern, 3008, Switzerland

Location

Biospecimen

Retention: SAMPLES WITH DNA

Mucosal swabs, intestinal mucosa and content, serum, mesenteric lymph node, subcutaneous biopsy

MeSH Terms

Conditions

Surgical Wound Infection

Condition Hierarchy (Ancestors)

Wound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Guido Beldi

    Department of Visceral Surgery and Medicine, Bern University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
4 Weeks
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 7, 2023

First Posted

March 20, 2023

Study Start

February 27, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 29, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations